---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-22-024600"
form_type: "8-K"
ticker: "KURA"
cik: "0001422143"
company_name: "Kura Oncology, Inc."
filed_at: "2022-02-01T23:59:59+00:00"
generated_at: "2026-06-27T12:54:01.867983+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Kura Oncology CFO Marc Grasso resigns; Doyle named principal accounting officer, CEO Wilson principal financial officer

## Summary
- CFO Marc Grasso resigns effective Feb 4, 2022 for family reasons; will provide up to 3 months advisory services with equity vesting.
- Thomas Doyle appointed SVP Finance & Accounting/principal accounting officer effective Feb 7; base salary $333,500, bonus up to 35%, option for 39,281 shares and 8,390 RSUs.
- CEO Troy Wilson appointed principal financial officer effective Feb 7.
- Doyle's option vests over 48 months; RSU vests over 4 years; severance includes 9 months salary plus COBRA.
- If within 12 months of change of control, Doyle receives lump sum of 9 months salary plus full target bonus.

## SEC filing metadata
- accession: 0001193125-22-024600
- form_type: 8-K
- ticker: KURA
- cik: 0001422143
- company_name: Kura Oncology, Inc.
- filed_at: 2022-02-01T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 5.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1422143/000119312522024600/0001193125-22-024600-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1422143/000119312522024600/d661588d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-22-024600
- JSON: https://secwatch.observer/filing/0001193125-22-024600.json
- Plain text: https://secwatch.observer/filing/0001193125-22-024600.txt

## Key facts
- Executive change
  Marc Grasso resigned as Chief Financial Officer at Kura Oncology, Inc..
  - Action: resigned
  - Role: Chief Financial Officer
  source text: On January 26, 2022, Marc Grasso, M.D. notified Kura Oncology, Inc. (the “Company”) of his intention to resign from his positions as the Company’s Chief Financial Officer and Chief Business Officer, principal accounting officer and principal financial officer, effective as of February 4, 2022 (the “Separation Date”), in order to pursue opportunities closer to his family.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1422143/000119312522024600/0001193125-22-024600-index.htm
- Executive change
  Troy E. Wilson was appointed as Principal Financial Officer at Kura Oncology, Inc..
  - Action: appointed
  - Role: Principal Financial Officer
  source text: On January 31, 2022, the Board of Directors of the Company (the “Board”) appointed (i) Thomas Doyle, the Company’s Vice President, Finance, as the Company’s Senior Vice President, Finance and Accounting and as the Company’s principal accounting officer, and (ii) Troy E. Wilson, Ph.D., J.D., the Company’s President and Chief Executive Officer, as the Company’s principal financial officer, each effective as of February 7, 2022.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1422143/000119312522024600/0001193125-22-024600-index.htm
- Executive change
  Thomas Doyle was appointed as Senior Vice President, Finance and Accounting, Principal Accounting Officer at Kura Oncology, Inc..
  - Action: appointed
  - Role: Senior Vice President, Finance and Accounting, Principal Accounting Officer
  source text: On January 31, 2022, the Board of Directors of the Company (the “Board”) appointed (i) Thomas Doyle, the Company’s Vice President, Finance, as the Company’s Senior Vice President, Finance and Accounting and as the Company’s principal accounting officer, and (ii) Troy E. Wilson, Ph.D., J.D., the Company’s President and Chief Executive Officer, as the Company’s principal financial officer, each effective as of February 7, 2022.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1422143/000119312522024600/0001193125-22-024600-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.